CLINICAL_TRIALS
trial_result
· 2024-07-23
Clinical Trial Update: Study of VIB7734 for the Treatment of Moderate to Severely Active SLE [Phase 2]
Summary
Phase 2 study of VIB7734 in moderate-to-severe systemic lupus erythematosus has completed, with results posted in 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Amgen | Conditions: Lupus Erythematosus, Systemic | Phase 2 | Status: COMPLETED | Results posted: 2024-07-23